MRKR
Marker Therapeutics, Inc.
There isn't enough reported data to score MRKR yet.
MRKR Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Unavailable | |
| Unavailable |
MRKR's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
MRKR PE Valuation
MRKR has no meaningful PE right now: it lost money over the past year.
MRKR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Stable | |
| -- | |
| Limited | |
| Low |
Analysts expect MRKR's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
MRKR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.47 | +$0.89 |
| Q1 2026 | -$0.67 | +$0.65 |
| Q4 2025 | -$0.91 | +$0.28 |
| Q3 2025 | -$1.22 | -$0.12 |
| Q2 2025 | -$1.36 | -$0.18 |
| Q1 2025 | -$1.32 | -$0.68 |
| Q4 2024 | -$1.19 | -$0.25 |
| Q3 2024 | -$1.10 | $0.00 |
MRKR is still losing money, but far less than before: $0.47 per share over the past year, against $70.80 at its worst in late 2019.
MRKR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $751.7K | +115% |
| Q4 2025 | $1.1M | -51% |
| Q3 2025 | $1.2M | -36% |
| Q2 2025 | $861.2K | -26% |
| Q1 2025 | $349.1K | -72% |
| Q4 2024 | $2.3M | +113% |
| Q3 2024 | $1.9M | +648% |
| Q2 2024 | $1.2M | +53% |
MRKR's revenue is recovering but still below its 2023 peak: $751,691 last quarter, up 115% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -542% | +778 points |
| Q4 2025 | -171% | +0.7 points |
| Q3 2025 | -173% | -49 points |
| Q2 2025 | -495% | -297 points |
| Q1 2025 | -1320% | -1115 points |
| Q4 2024 | -171% | +107 points |
| Q3 2024 | -125% | +1118 points |
| Q2 2024 | -197% | +345 points |
MRKR's operating margin was −542% last quarter, up 778 points from the same quarter a year ago.
MRKR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.7M | -$1.8M |
| Q1 2026 | -$1.4M | +$4.1M |
| Q4 2025 | -$1.9M | +$2.8M |
| Q3 2025 | -$2.7M | -328% |
| Q2 2025 | -$1.9M | +$1.7M |
| Q1 2025 | -$5.5M | -$1.7M |
| Q4 2024 | -$4.7M | -$2.3M |
| Q3 2024 | $1.2M | +$2.3M |
MRKR has burned cash in almost every quarter: −$10M over the past year, against −$11M the year before.
MRKR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +38% | +5.4M shares |
| 3 years | +120% | +10.5M shares |
| 5 years | +133% | +11M shares |
| Available history | +323% | +14.7M shares |
MRKR has 19M diluted shares, up 38% from a year ago.
MRKR Net Leverage
MRKR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MRKR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.7 | Neutral |
| Stochastic | 7.4 | Oversold |
MRKR's weekly RSI is 37 (neutral) and its Stochastic is 7 (oversold).
MRKR PE vs Healthcare Sector
MRKR has no meaningful PE right now: it lost money over the past year.
MRKR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.99 | 9.1% below |
| 20 week MA | $1.16 | 22% below |
| 50 week MA | $1.36 | 34% below |
| 100 week MA | $1.42 | 37% below |
| 200 week MA | $2.53 | 64% below |
MRKR is in a downtrend: it's below all five of its weekly moving averages, and 64% below its 200-week average.
MRKR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $30.7 | $15.3 | -50% |
| 2021 | $15.3 | $9.98 | -35% |
| 2022 | $9.98 | $2.60 | -74% |
| 2023 | $2.60 | $5.50 | +112% |
| 2024 | $5.50 | $3.49 | -37% |
| 2025 | $3.49 | $1.44 | -59% |
| 2026 YTD | $1.44 | $0.90 | -38% |
MRKR's yearly returns have swung widely, from +112% in 2023 to −74% in 2022. It's down 38% so far in 2026.